A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Sjogren Disease

In brief

This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.

Key facts

Study ID
NCT06928142
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
People needed
83
Starts
2025-04-23
Expected to finish
2027-06-04
Last updated by the study team
2026-03-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.